research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
Search
for
Sort by
Research
210-240 / 1000+ resultsresearch A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice
research Dutasteride in Androgenetic Alopecia: An Update
Dutasteride is becoming a popular hair loss treatment, proving more effective than finasteride with similar side effects.
research Low-Dose Flutamide (125 mg/Day) as Maintenance Therapy in the Treatment of Hirsutism
Low-dose flutamide effectively maintains reduced hirsutism with no side effects.
research The 5α-reductase inhibitor finasteride reduces opioid self-administration
Finasteride may help reduce opioid use.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Pharmacological basis for clinical use of antiandrogens
Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by blocking male sex hormones.
research Is Dutasteride a Therapeutic Alternative for Amyotrophic Lateral Sclerosis?
Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
research Cortexolone 17a-propionate: A new antiandrogen acting on hair dermal papilla cells for the treatment of androgenic alopecia
Cortexolone 17a-propionate may be an effective new treatment for hair loss.
research 5α-Reductase inhibitors in androgenetic alopecia
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Azasteroids as inhibitors of testosterone 5α-reductase in mammalian skin
Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.
research Synthesis and Evaluation of 2‘-Substituted 4-(4‘-Carboxy- or 4‘-carboxymethylbenzylidene)-N-acylpiperidines: Highly Potent and in Vivo Active Steroid 5α-Reductase Type 2 Inhibitors
Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research 17α-Acetoxy-6-bromo-16β-methylpregna-4,6-diene-3,20-dione
A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
Deucravacitinib helped a man regrow hair and improve psoriasis.
research Die kontrazeptive Betreuung androgenisierter Frauen mit einem niedrig dosierten cyproteronacetathaltigen Einphasenpräparat
Diane is effective for treating acne, seborrhoea, androgenic alopecia, and mild hirsutism in women.
research No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research Effective treatment of female androgenic alopecia with dutasteride.
Dutasteride successfully treated a woman's hair loss when other treatments failed.
research Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
research Effects of antiandrogen therapy of cyproteron acetate on androgen effects on the skin including androgenetic alopecia in menopausal women – case report: 10 years follow up –
Cyproterone acetate therapy improved hair loss and reduced testosterone levels in a menopausal woman.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Intralesional Pentoxifylline Injection Versus Triamcinolone Acetonide in Treating localized Alopecia Areata: A Comparative Study.
Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
research Dutasteride mesotherapy in the treatment of androgenetic alopecia
Dutasteride injections can help treat hair loss in men and women.
research Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line
Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.